Author: Griese M. App E.M. derouix A. Burkert A. Schams A.
Publisher: Academic Press
ISSN: 1094-5539
Source: Pulmonary Pharmacology & Therapeutics, Vol.10, Iss.1, 1997-02, pp. : 21-27
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Cystic fibrosis (CF) is caused by mutation in the gene for the CF transmembrane conductance regulator which leads to massive, abnormally viscous, purulent sputum, chronic destructive endobronchitis and early death. Purified recombinant human (rh) DNase can digest extracellular DNA and its inhalation in these patients significantly improves lung function. To evaluate the poorly understood mechanisms, saliva protected sputum from patients treated with and without rhDNase were evaluated. Therapy with rhDNase resulted in a soluble sputum fraction that had a higher percentage of phosphatidylethanolamine, a phospholipid present mainly in cellular membranes, a much lower percentage of phosphatidylcholine, but a higher surface activity. The rigidity was significantly lower and the ratio of viscosity in proportion to elasticity increased. All these data are consistent with an increased clearability of the sputum by coughing, but not by mucociliary activity. Thus the interaction of inhaled rhDNase with the purulent mucus and the endobronchial inflammatory processes may induce changes that result in rheological properties favoring clearance of sputum by cough.
Related content
Recombinant Human Antithrombin III: rhATIII
Drugs in R&D, Vol. 5, Iss. 2, 2004-01 ,pp. :
DNASE1L3 Mutations in Hypocomplementemic Urticarial Vasculitis Syndrome
Arthritis & Rheumatism, Vol. 65, Iss. 8, 2013-08 ,pp. :
Drug Disposition in Cystic Fibrosis
By Rey E. Tréluyer J-M. Pons G.
Clinical Pharmacokinetics, Vol. 35, Iss. 4, 1998-10 ,pp. :